The use of tiagabine and gabapentin in the treatment of social anxiety disorder in 8 patients
Gabapentin and tiagabine for treatment of social anxiety disorder in 8 patients in a random double blind crossover study with outcome measured as changes in the Leibowitz Social Anxiety Scale
Maria Urbano, M.D.
8 participants
May 20, 2003
Interventional
Conditions
Summary
Social Anxiety Disorder creates stress and significant disability for patients. Common treatments like selective serotonin reuptake inhibitors and benzodiazepines have undesirable side effects like sexual dysfunction or the potential for drug abuse/ dependence. The objective of the study was to see if alternative medications - tiagabine and gabapentin - already shown to be effective in other anxiety disorders might be effective for social anxiety disorder too. Subjects were selected to have social anxiety disorder by meeting the DSM-IV criteria and having a high score on the Liebowitz Social Anxiety Scale. Subjects were chosen who were generally healthy and had no other psychiatric diagnoses. They received a physical exam and lab work before starting the study. Each individual received each medication at a steady dosage for 4 weeks after being slowly increased for two weeks. The subjects took a Liebowitz Social Anxiety Scale and Clinical Global Impression Scale on each visit as well as reported efficacy of the medication (unknown to the patient or the investigator) and any side effects. Eight patients completed the study. Both medications were well tolerated with sedation and mild dizziness being the most common. All subjects with severe social anxiety responded well to both medications with two subjects reaching remission of symptoms. Gabapentin and tiagabine should be considered as effective alternate treatments for social anxiety disorder.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each subject was titrated to either 1800 mg gabapentin oral tablets daily or 2400 mg tiagabine oral tablets daily by mouth and stayed at that dosage for 4 weeks before being washed out for 2 weeks and receiving whichever medication they had not initially received.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000091202